Giant-Cell Arteritis Market Report 2024

The giant-cell arteritis market size has grown steadily in recent years. It will grow from $1.02 billion in 2023 to $1.07 billion in 2024 at a compound annual growth rate (CAGR) of 4.9%. The growth observed in the historic period can be attributed to several factors, including advancements in epidemiological studies, deeper genetic insights into diseases, increased adoption of biologics in treatment, advancements in diagnostic techniques, and the development of targeted therapies and biologics tailored to specific conditions.

The giant-cell arteritis market size is expected to see strong growth in the next few years. It will grow to $1.3 billion in 2028 at a compound annual growth rate (CAGR) of 5.1%. In the forecast period, growth can be attributed to increasing rates of diagnosis, an aging population, rising healthcare expenditure, heightened patient advocacy, and expansion into new geographic regions. Major trends expected in this period include advancements in the identification and validation of biomarkers, the development of therapies targeting specific molecular pathways, adoption of advanced imaging techniques, innovations in drug delivery methods, and the utilization of AI algorithms for predictive analytics.

The increasing focus on personalized medicine is expected to drive growth in the giant-cell arteritis market in the coming years. Personalized medicine involves tailoring medical treatments to individual characteristics such as genetics, lifestyle, and environmental factors. This approach is gaining momentum due to advancements in genomics, biotechnology, and data analytics, which enable more precise therapies that enhance treatment effectiveness and minimize side effects for patients. In the context of giant-cell arteritis (GCA), personalized medicine can lead to targeted therapies based on factors such as genetic predispositions, immune responses, and specific disease symptoms. For example, according to the Personalized Medicine Coalition (PMC) in February 2024, over one-third of new drug approvals by the U.S. Food and Drug Administration (FDA) in 2023 were for personalized medicines. This marked the fourth consecutive year of significant growth, with 16 new treatments tailored for rare diseases approved, compared to six approvals in 2022. These approvals included medications for cancer and other conditions, underscoring the increasing adoption of personalized approaches in healthcare and their impact on disease management such as GCA.

Leading companies in the giant-cell arteritis market are advancing by introducing new products such as biosimilars to expand treatment options and meet patient needs. Biosimilars are biologic drugs highly similar to approved biological products, ensuring no clinically meaningful differences in safety, purity, and potency. For instance, in April 2024, Fresenius SE & Co. KGaA launched Tocilizumab-aazg in the U.S., a biosimilar approved for chronic autoimmune diseases including rheumatoid arthritis (RA), systemic juvenile idiopathic arthritis (JIA), polyarticular juvenile idiopathic arthritis (PJIA), and giant cell arteritis. Its approval followed a comprehensive evaluation in a phase 1 trial comparing its pharmacokinetics, safety, and immunogenicity to reference tocilizumab products.

In April 2023, Marksans Pharma, an India-based pharmaceutical company, acquired Teva’s manufacturing facility in Goa, India, enhancing its production capacity significantly. This acquisition doubles Marksans Pharma's manufacturing capabilities in India, enabling the production of various pharmaceutical products including tablets, capsules, ointments, liquids, and creams. Teva Pharmaceutical, based in Israel, is known for its contributions in producing medications such as prednisone tablets used in the treatment of giant-cell arteritis.

Major companies operating in the giant-cell arteritis market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., CSL Limited, Kiniksa Pharmaceuticals Ltd., MorphoSys AG.

North America was the largest region in the giant-cell arteritis market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the giant-cell arteritis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the giant-cell arteritis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Giant-cell arteritis (GCA) is a form of vasculitis, characterized by inflammation of medium to large arteries. It often affects the temporal arteries, causing symptoms such as headaches, scalp tenderness, and vision issues. If untreated, GCA can lead to severe complications such as blindness or stroke due to inflammation of vessel walls. Treatment typically involves high doses of corticosteroids to reduce inflammation and prevent complications.

Common therapeutics for giant-cell arteritis include prednisone, methotrexate, tocilizumab, and aspirin. Prednisone, a corticosteroid, works by suppressing inflammation and immune responses. It is administered via various routes such as oral, intravenous, and subcutaneous, and is utilized for its anti-inflammatory, immunosuppressive, and anticoagulant properties.

The giant-cell arteritis market research report is one of a series of new reports that provides giant-cell arteritis market statistics, including giant-cell arteritis industry global market size, regional shares, competitors with a giant-cell arteritis market share, detailed giant-cell arteritis market segments, market trends and opportunities, and any further data you may need to thrive in the giant-cell arteritis industry. This giant-cell arteritis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The giant-cell arteritis market consists of revenues earned by entities by services such as monitoring and follow-up, supportive care, diagnostic testing, treatment administration. The market value includes the value of related goods sold by the service provider or included within the service offering. The giant-cell arteritis market also includes sales of biologics, diagnostic tools, biopsy kits and related products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.